Tandem Diabetes Care has received FDA clearance for the Android version of the Tandem Mobi mobile app, set for limited release in December 2025 and broader availability in early 2026. This app will enhance accessibility to Tandem’s automated insulin delivery system for users with compatible Android smartphones. The company plans to launch the t:slim X2’s integration with Abbott’s FreeStyle Libre 3 Plus CGM sensor in October 2025, aiming to attract more continuous glucose monitoring users. Analysts project Tandem Diabetes Care could achieve .2 billion in revenue and .4 million in earnings by 2028, assuming a 7.5% annual revenue growth rate. Fair value estimates for the stock range from .64 to .57 per share, indicating a potential downside from its current market price.